未名医药股权案二审改判：刑期罚金大减

Core Viewpoint - The second-instance judgment by the Zibo Intermediate People's Court on the equity dispute case of Weiming Pharmaceutical (ST Weiming, 002581.SZ) has significantly reduced the penalties for the defendants, indicating a shift in the court's interpretation of the actions taken by the defendants regarding the company's equity structure and control [2][5][6]. Group 1: Court Rulings and Defendants - The court sentenced defendant Pan Aihua to five years in prison for embezzlement and ordered him to return 12.75 million RMB to Weiming Biopharmaceutical Co., Ltd [2][5]. - Li Pengfei was sentenced to two years for forgery of state documents and one year for forgery of company seals, with fines totaling 80,000 RMB [2][5]. - The court found that the actions of the defendants did not constitute embezzlement, as the changes in equity did not result in actual financial loss to the company [6][7]. Group 2: Background of the Case - The case traces back to August 2022 when the Shenzhen Stock Exchange issued a notice regarding investor complaints about a 2.9 billion RMB investment by Hangzhou Qiangxin into Weiming's subsidiary, Xiamen Weiming, which resulted in a 34% equity stake [3][4]. - Weiming Pharmaceutical claimed that this transaction led to a significant loss of core assets and reported the matter to the Zibo Public Security Bureau [3][4]. - Following the investigation, Weiming Pharmaceutical transferred its 26.91% stake in Beijing Kexing to regain control over its assets [3][4]. Group 3: Legal Interpretation and Defense - The court determined that the investment by Hangzhou Qiangxin was an abnormal capital increase, but it did not meet the criteria for embezzlement due to the lack of actual financial damage to the company [6][7]. - The defense argued that the actions of the defendants were aimed at maintaining control over the company rather than illegally appropriating assets, emphasizing that the changes in equity did not lead to any financial loss or benefit for the defendants [8].